Dr Reddy's Laboratories share price, financials and monitoring
Dr Reddy's Laboratories operates across generics, branded formulations, pharmaceutical services and active ingredients. Product mix, launches, price erosion, R&D, regulatory outcomes, currency and cash conversion explain more than consolidated revenue alone.
FY26 and the latest quarter
The annual and quarterly numbers below come from the current point-in-time serving views. Consolidated results are preferred and the source is retained where it is publicly linkable.
Revenue history
A rising top line is evidence of scale, not proof of value creation. Read it with profit, capital efficiency, cash conversion and the business-specific guideposts above.
₹ crore values are presented as filed or normalized from company/exchange financial results. Banks and NBFCs use total income because interest is part of their operating business. Industrial companies use revenue where available.
Historical values can be restated. This page shows the current serving vintage and preserves the source and reporting basis.
| Fiscal year | Revenue | PAT | EPS | Basis | Evidence |
|---|---|---|---|---|---|
| FY2231 Mar 2022 | ₹21,545 cr | ₹2,183 cr | 131.57 | Consolidated | Filing ↗ |
| FY2331 Mar 2023 | ₹24,670 cr | ₹4,507 cr | 271.47 | Consolidated | Filing ↗ |
| FY2431 Mar 2024 | ₹28,011 cr | ₹5,578 cr | 335.22 | Consolidated | Filing ↗ |
| FY2531 Mar 2025 | ₹32,644 cr | ₹5,725 cr | 67.89 | Consolidated | Filing ↗ |
| FY2631 Mar 2026 | ₹33,700 cr | ₹4,158 cr | 50.41 | Consolidated | Filing ↗ |
Eight reported quarters
Publication date is shown separately from the period end. A June quarter was not knowable on 30 June; it entered the public record only when the company filed it.
| Quarter ended | Revenue | Attributable PAT | EPS | Published | Evidence |
|---|---|---|---|---|---|
| 30 Jun 2026Consolidated | ₹8,100 cr | ₹444 cr | 5.33 | 22 Jul 2026 | Filing ↗ |
| 31 Mar 2026Consolidated | ₹7,546 cr | ₹221 cr | 2.65 | 12 May 2026 | Filing ↗ |
| 31 Dec 2025Consolidated | ₹8,753 cr | ₹1,210 cr | 14.53 | 21 Jan 2026 | Filing ↗ |
| 30 Sept 2025Consolidated | ₹8,828 cr | ₹1,347 cr | 16.18 | 24 Oct 2025 | Filing ↗ |
| 30 Jun 2025Consolidated | ₹8,572 cr | ₹1,418 cr | 17.04 | 23 Jul 2025 | Filing ↗ |
| 31 Mar 2025Consolidated | ₹8,528 cr | ₹1,593 cr | 19.12 | 9 May 2025 | Filing ↗ |
| 31 Dec 2024Consolidated | ₹8,381 cr | ₹1,414 cr | 16.97 | 23 Jan 2025 | Filing ↗ |
| 30 Sept 2024Consolidated | ₹8,038 cr | ₹1,256 cr | 15.08 | 5 Nov 2024 | Filing ↗ |
Use the metric that fits the business.
ROCE is not shown for banks and NBFCs because deposits and borrowings are operating raw material rather than ordinary financing. Missing or inapplicable values remain unavailable.
Who owns the company?
Shareholding is shown from the latest available filing. Institutional subtotals depend on the filing taxonomy and are labelled by their source basis.
Profit is only one part of the evidence.
These are investigation prompts, not pass-or-fail verdicts. Business model, working-capital structure and reporting basis determine how each value should be interpreted.
Current, sourced and intentionally finite.
This public page contains a selected, licensable subset of Altys company data. It does not expose private research notes, broker documents, user portfolios or the company database.
Related company and methodology pages
Dr Reddy's Laboratories FAQ
What does Dr Reddy's Laboratories do?
Dr Reddy's Laboratories operates across generics, branded formulations, pharmaceutical services and active ingredients. Product mix, launches, price erosion, R&D, regulatory outcomes, currency and cash conversion explain more than consolidated revenue alone.
What should investors monitor for Dr Reddy's Laboratories?
Important operating evidence includes north america product mix, india and emerging-market growth, new launches, price erosion, r&d and regulatory events, margins and cash conversion. These are research guideposts, not automatic trading signals.
Are the Dr Reddy's Laboratories financials consolidated or standalone?
Altys prefers consolidated financials when available and labels the reporting basis in each table. The latest annual row on this page is consolidated.
Does Altys recommend buying or selling Dr Reddy's Laboratories?
No. Altys provides sourced financial data, research context and monitoring infrastructure. It does not issue a buy, sell or hold recommendation on this page.
Research Dr Reddy's Laboratories once. Keep watching what changes.
Altys can connect new results, filings, concalls, guidance, ownership and company-specific KPIs with the investment team’s original thesis and portfolio context.